CollPlant Biotechnologies Q1 EPS $(0.29), Inline, Sales $433.00K Beat $240.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
CollPlant Biotechnologies reported Q1 losses of $(0.29) per share, in line with analyst estimates, and sales of $433K, beating the $240K estimate by 80.42%. This represents a 556.06% increase in sales compared to the same period last year.
May 24, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CollPlant Biotechnologies' Q1 earnings met analyst expectations with losses of $(0.29) per share, while sales of $433K exceeded estimates by 80.42% and grew 556.06% YoY.
CollPlant Biotechnologies' Q1 earnings report shows strong sales growth of 556.06% YoY and beating analyst estimates by 80.42%. This positive performance is likely to have a short-term positive impact on the stock price, as it demonstrates the company's ability to generate revenue and meet expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100